Tasigna (nilotinib) was developed by Novartis to treat chronic Myeloid leukemia. It belongs to the tyrosine kinase inhibitor (TKI) family and specifically works to prohibit blood cancer cell growth.
Lawsuits Novartis is Facing
Novartis is being sued by several civilian parties for its failure to provide a proper warning to its patients in the United States about its grave side effects. A settlement has not yet been reached, although Novartis has paid a large settlement to the United States Department of Justice for illegal actions such as its marketing practices.
Despite mounting evidence, Novartis still has not warned its American cancer patients about the serious side effects of taking oral Tasigna. While the FDA has not stepped in to warn or protect patients either, under the Food and Drug Administration Safety and Innovation Act (FDASIA), they are charged with protecting patient safety when it comes to warnings about prescription drugs. Patients may need to hold them liable for their actions through a civil lawsuit with the help of a lawyer familiar with Tasigna cases.
